Data-driven drug development
18 January 2019
Robert Roe looks at regulatory and technological changes that are changing the way drug development is carried out
Robert Roe interviews MathWorks Loren Dean, on the use of AI in modelling and simulation
drug discovery
Latest issue
Every device needs to work seamlessly in its operating environment. But when that environment is a human body, things get complicated.
Christian Marcazzo, general manager at IDBS, highlights trends in life sciences research and development.
Data is a company’s biggest asset, yet for any organisation, keeping a handle on the potentially vast volumes and diversity of data that are generated can represent a considerable issue.
Rob Lalonde, Univa’s cloud VP general manager, considers the unique challenges posed by HPC
Deep learning has seen a huge rise in popularity over the last five years in both enterprise and scientific applications.
HPC users are increasingly turning to cloud technologies due to their flexibility and scalability, allowing them to quickly change the size of their workloads, adopt new technologies in a small testing environment and to help to increase the agility of a company working across multiple sites, or
